<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1177" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1177/" /><meta name="ncbi_pagename" content="Nephrogenic Diabetes Insipidus - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Nephrogenic Diabetes Insipidus - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Nephrogenic Diabetes Insipidus" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2012/06/14" /><meta name="citation_author" content="Nine Knoers" /><meta name="citation_pmid" content="20301356" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1177/" /><meta name="citation_keywords" content="Nephrogenic Diabetes Insipidus, X-Linked" /><meta name="citation_keywords" content="Nephrogenic Diabetes Insipidus, Autosomal" /><meta name="citation_keywords" content="Aquaporin-2" /><meta name="citation_keywords" content="Vasopressin V2 receptor" /><meta name="citation_keywords" content="AQP2" /><meta name="citation_keywords" content="AVPR2" /><meta name="citation_keywords" content="Nephrogenic Diabetes Insipidus" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Nephrogenic Diabetes Insipidus" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Nine Knoers" /><meta name="DC.Date" content="2012/06/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1177/" /><meta name="description" content="Nephrogenic diabetes insipidus (NDI) is characterized by inability to concentrate the urine, which results in polyuria (excessive urine production) and polydipsia (excessive thirst). Affected untreated infants usually have poor feeding and failure to thrive, and rapid onset of severe dehydration with illness, hot environment, or the withholding of water. Short stature and secondary dilatation of the ureters and bladder from the high urine volume is common in untreated individuals." /><meta name="og:title" content="Nephrogenic Diabetes Insipidus" /><meta name="og:type" content="book" /><meta name="og:description" content="Nephrogenic diabetes insipidus (NDI) is characterized by inability to concentrate the urine, which results in polyuria (excessive urine production) and polydipsia (excessive thirst). Affected untreated infants usually have poor feeding and failure to thrive, and rapid onset of severe dehydration with illness, hot environment, or the withholding of water. Short stature and secondary dilatation of the ureters and bladder from the high urine volume is common in untreated individuals." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1177/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ndi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1177/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DA441E040621100000000088B02FA.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1177_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1177_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/nem/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/nephron-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1177_"><span class="title" itemprop="name">Nephrogenic Diabetes Insipidus</span></h1><p class="contrib-group"><span itemprop="author">Nine Knoers</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1177_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1177_ai__"><div class="contrib half_rhythm"><span itemprop="author">Nine Knoers</span>, MD, PhD<div class="affiliation small">Medical Genetics<br />University Medical Center<br />Utrecht, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.thcertucmu@sreonk.a.v.v" class="oemail">ln.thcertucmu@sreonk.a.v.v</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 12, 2000</span>; Last Update: <span itemprop="dateModified">June 14, 2012</span>.</p><p><em>Estimated reading time: 26 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ndi.Summary" itemprop="description"><h2 id="_ndi_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Nephrogenic diabetes insipidus (NDI) is characterized by inability to concentrate the urine, which results in polyuria (excessive urine production) and polydipsia (excessive thirst). Affected untreated infants usually have poor feeding and failure to thrive, and rapid onset of severe dehydration with illness, hot environment, or the withholding of water. Short stature and secondary dilatation of the ureters and bladder from the high urine volume is common in untreated individuals.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The clinical diagnosis of NDI relies on demonstration of subnormal ability to concentrate the urine despite the presence of the antidiuretic hormone pituitary-derived arginine vasopressin (AVP). Pathogenic variants in two genes are known to cause NDI &#x02013; <i>AVPR2</i> (<a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>) and <i>AQP2</i> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management by a team (nutritionist, pediatric nephrologist/endocrinologist, clinical geneticist); free access to drinking water and to toilet facilities; reduction of polyuria (and thus polydipsia) up to 50% without inducing hypernatremia by use of one of the following: thiazide diuretics (i.e., hydrochlorothiazide, chlorothiazide) and/or other diuretics (i.e., potassium-sparing diuretic amiloride), dietary restriction of sodium, use of nonsteroidal anti-inflammatory drugs; in individuals with dehydration or shock, establish whether the deficit is primarily in free water (through water deprivation or excessive urine, stool, or sweat) or in extracellular fluid (bleeding, fluid extravasation) to avoid inappropriate treatment of dehydration with normal saline (0.9% NaCl); treat hydronephrosis, hydroureter, and megacystis with medical management to reduce urine output and continuous or intermittent bladder catheterization when post-void urinary bladder residuals are significant; when "NPO" (nothing <i>per ora)</i>, individuals with NDI <i>must</i> have intravenous replacement of their usual oral intake of water as 2.5% dextrose in water.</p><p><i>Surveillance:</i> Monitoring of growth and development in infants and children; periodic measurement of serum sodium concentration to identify unrecognized hyperosmolality and early dehydration; annual renal ultrasound evaluation to monitor for hydronephrosis and megacystis.</p><p><i>Agents/circumstances to avoid:</i> Water intake must not be restricted.</p><p><i>Evaluation of relatives at risk:</i> Evaluation of at-risk infants as early as possible to allow for prompt diagnosis and treatment to reduce morbidity from hypernatremia, dehydration, and dilation of the urinary tract.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>NDI is most commonly inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner (~90% of individuals). NDI can also be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner (~9% of individuals) or in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner (~1% of individuals). The risks to sibs and offspring depend on the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> and the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of the parents, which can be established in most families using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Prenatal testing is possible for at-risk pregnancies if the disease-causing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family have been identified.</p></div></div><div id="ndi.Diagnosis"><h2 id="_ndi_Diagnosis_">Diagnosis</h2><div id="ndi.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>Nephrogenic diabetes insipidus (NDI) is suspected in individuals with:</p><ul><li class="half_rhythm"><div>Polyuria (excessive urine production)</div></li><li class="half_rhythm"><div>Polydipsia (excessive drinking)</div></li></ul></div><div id="ndi.Testing"><h3>Testing</h3><div id="ndi.Tests_of_UrineConcentrating_Ability"><h4>Tests of Urine-Concentrating Ability</h4><p><b>Affected individuals</b></p><ul><li class="half_rhythm"><div><b>Measurement of serum sodium concentration</b> with simultaneous measurement of urine specific gravity is the most helpful screening test for diabetes insipidus. An increased serum sodium concentration (&#x0003e;143 mEq/L) in the presence of a low urine specific gravity and in the absence of excessive sodium intake is highly suggestive of diabetes insipidus.</div></li><li class="half_rhythm"><div><b>Failure to concentrate the urine</b> normally in the presence of high plasma vasopressin concentration and after parenteral administration of vasopressin or desmopressin (DDAVP<sup>&#x000ae;</sup>) is diagnostic of NDI. Administration of 10 to 40 &#x000b5;g DDAVP<sup>&#x000ae;</sup> intranasally in individuals older than age one year usually results in a urine osmolality that is:</div><ul><li class="half_rhythm"><div>&#x0003e;807 mOsm/kg H<sub>2</sub>O in normal individuals;</div></li><li class="half_rhythm"><div>&#x0003c;200 mOsm/kg H<sub>2</sub>O in individuals with NDI [<a class="bk_pop" href="#ndi.REF.van_lieburg.1999.1958">van Lieburg et al 1999</a>].</div></li></ul></li></ul><p>Note: The results of these tests may be difficult to interpret in individuals with "partial diabetes insipidus," which results from either subnormal amounts of vasopressin secretion (partial neurogenic DI) or partial response of the kidney to normal vasopressin concentrations (partial nephrogenic DI). These two disorders can be distinguished by comparing the ratio of urine osmolarity to plasma vasopressin concentration against normal standards. However, direct measurement of vasopressin is hampered by technical difficulties. Recently, it has been shown that copeptin, which is the C-terminal component of the AVP-precursor and co-secreted with AVP, is much easier to measure than AVP and a valuable surrogate of AVP. As such, it holds promise as a diagnostic tool in polyuria-polydipsia syndromes [<a class="bk_pop" href="#ndi.REF.fenske.2011.1506">Fenske et al 2011</a>].</p><p><b>Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI.</b> An overnight urinary concentration test in female relatives, proposed as a method of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> detection, is unreliable.</p></div><div id="ndi.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b><i>AVPR2</i></b> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is known to cause <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> nephrogenic diabetes insipidus.</p><p><b><i>AQP2</i></b> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is known to cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> nephrogenic diabetes insipidus.</p><div id="ndi.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in NDI</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1177/table/ndi.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ndi.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of NDI Attributed to Mutation of This Gene</th><th id="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Gene &#x00026; Test Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>AVPR2</i></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">90%</td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95% of individuals w/XL NDI</td></tr><tr><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exon &#x00026; whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications</td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Linkage analysis&#x000a0;<sup>7</sup></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Not applicable</td></tr><tr><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>AQP2</i></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">~10%</td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~95% of individuals w/AR or AD NDI</td></tr><tr><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Linkage analysis&#x000a0;<sup>7</sup></td><td headers="hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_ndi.T.molecular_genetic_testing_used_in_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Not applicable</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="ndi.TF.1.1"><p class="no_margin">See <a href="/books/NBK1177/#ndi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ndi.TF.1.2"><p class="no_margin">See <a href="#ndi.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="ndi.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="ndi.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="ndi.TF.1.5"><p class="no_margin">Testing that identifies deletions/duplications not readily detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>6. </dt><dd><div id="ndi.TF.1.6"><p class="no_margin">Exon and partial- and whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions have been reported (see <a href="/books/NBK1177/#ndi.molgen.TA">Table A. Genes and Databases</a>, <b>HGMD</b>).</p></div></dd><dt>7. </dt><dd><div id="ndi.TF.1.7"><p class="no_margin">Linkage testing cannot be used to confirm the diagnosis of NDI [<a class="bk_pop" href="#ndi.REF.arthus.2000.1044">Arthus et al 2000</a>]. However, if the family <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> structure is sufficient and family members are cooperative with the testing process, linkage analysis may be performed to confirm cosegregation of a potential <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> with the disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in individual families.</p></div></dd></dl></div></div></div></div></div><div id="ndi.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Because most NDI is caused by <i>AVPR2</i> pathogenic variants, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of a symptomatic individual, male or female, usually starts with <i>AVPR2</i> sequencing. If no pathogenic variants are found, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> is performed, followed by <i>AQP2</i> sequencing</div></li><li class="half_rhythm"><div>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children (male or female) from <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> parents, <i>AQP2</i> sequencing is performed first. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AQP2</i> is identified, <i>AVPR2</i> sequencing is performed.</div></li></ul><p><b>Carrier testing for female relatives</b> at risk for <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p>Note: (1) Carriers are heterozygotes for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder and may develop clinical findings related to the disorder. (2) Identification of female carriers requires either (a) prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p><b>Carrier testing for relatives</b> at risk for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI requires prior identification of the pathogenic variants in the family.</p><p>Note: Carriers are heterozygotes for this <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder and are not at risk of developing the disorder.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p></div></div><div id="ndi.Clinical_Characteristics"><h2 id="_ndi_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ndi.Clinical_Description"><h3>Clinical Description</h3><p><b>Nephrogenic diabetes insipidus (NDI).</b> Individuals with NDI typically have polyuria and polydipsia. However, in some infants, polydipsia and polyuria are often unappreciated or unremarkable. These infants may present with vomiting, gagging or retching, poor feeding, constipation or diarrhea, failure to thrive, unexplained fevers, and lethargy or irritability. The majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are diagnosed in the first year of life [<a class="bk_pop" href="#ndi.REF.van_lieburg.1999.1958">van Lieburg et al 1999</a>]. The initial symptoms in <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NDI usually appear later, in some cases not before early adulthood.</p><p>Other infants, as well as older individuals, may present with rapid onset of severe dehydration associated with water deprivation, a hot environment, or intercurrent illnesses associated with decreased water intake and/or increased free water losses through vomiting, diarrhea, or fever. Seizures and/or coma may occur with rapid increases or decreases in plasma osmolality. Occasionally, the presenting sign is hydronephrosis, hydroureter, or megacystis.</p><p>Dehydrated individuals who have not been diagnosed to have NDI or who are unable to communicate their complaints run the risk of being improperly treated with IV administration of normal saline, especially in emergency situations. This may exacerbate hypernatremia. Prolonged, unrecognized, or repeated episodes of hypernatremic dehydration may result in seizures, permanent brain damage, developmental delay, and cognitive impairment. With early diagnosis and proper management, intelligence and life span are usually normal.</p><p>Chronic excretion of large volumes of urine in untreated persons results in hydronephrosis, hydroureter, and megacystis (huge bladder). Some degree of urinary tract distension may be seen on ultrasound examination even in infants [<a class="bk_pop" href="#ndi.REF.yoo.2006.126">Yoo et al 2006</a>]. Potential complications of urinary tract dilatation are rupture of the urinary tract, infection, intractable pain, improper bladder function, and/or kidney failure. These complications may occur as early as the second decade of life [<a class="bk_pop" href="#ndi.REF.shalev.2004.608">Shalev et al 2004</a>]. Lifestyle is substantially affected by the need to have constant access to potable water and by the increased frequency of urination. The unavailability of restroom facilities, even for a short time, is a problem in societies in which public urination is taboo. School and other social or group activities may be disrupted.</p><p>Affected individuals are almost always less than 50th centile for height; most are more than one standard deviation below the mean. Failure to thrive or short stature may result from unsuccessful management or inadequate nutrition related to polydipsia. In the majority of cases catch-up growth does not occur later in childhood [<a class="bk_pop" href="#ndi.REF.van_lieburg.1999.1958">van Lieburg et al 1999</a>].</p><p><b>Partial nephrogenic diabetes insipidus.</b> Individuals with partial NDI tend to be diagnosed in later childhood. They usually do not have growth or developmental delay and are able to concentrate the urine in response to dehydration or DDAVP<sup>&#x000ae;</sup> administration, but to a lesser extent than unaffected individuals.</p><p><b>Heterozygotes for <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI.</b> Female carriers of X-linked NDI may have no symptoms or a variable degree of polyuria and polydipsia, or they may be as severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> as males. In females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <i>AVPR2</i> pathogenic variants, a correlation between urine-concentrating ability (and symptoms) and skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> in leukocytes has been reported [<a class="bk_pop" href="#ndi.REF.kinoshita.2004.167">Kinoshita et al 2004</a>, <a class="bk_pop" href="#ndi.REF.faerch.2010.324">Faerch et al 2010</a>].</p></div><div id="ndi.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI are similar with respect to initial symptoms and, with a few exceptions, age of onset.</p><p>In the minority of individuals with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI and an <i>AVPR2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in partial insensitivity to AVP or DDAVP<sup>&#x000ae;</sup>, disease onset may be later in childhood. Thus, three families had the <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant <a class="figpopup" href="/books/NBK1177/table/ndi.T.avpr2_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figndiTavpr2pathogenicvariantsdiscusse" rid-ob="figobndiTavpr2pathogenicvariantsdiscusse">p.Asp85Asn</a> associated with decreased ligand-binding affinity and decreased coupling to G<sub>s</sub>, and one had the missense variant <a class="figpopup" href="/books/NBK1177/table/ndi.T.avpr2_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figndiTavpr2pathogenicvariantsdiscusse" rid-ob="figobndiTavpr2pathogenicvariantsdiscusse">p.Gly201Asn</a> associated with a decreased number of cell surface AVPR2 receptors. An individual representing a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (a single <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in a family) had the missense variant <a class="figpopup" href="/books/NBK1177/table/ndi.T.avpr2_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figndiTavpr2pathogenicvariantsdiscusse" rid-ob="figobndiTavpr2pathogenicvariantsdiscusse">p.Pro322Ser</a>, which was able to partially activate the G<sub>s</sub>/adenylyl cyclase system.</p><p>Recently, two other pathogenic variants (p.Ser-333del and p.Tyr128Ser) were shown to result in a partial NDI <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. The partial loss of function of these variants results from defective membrane trafficking [<a class="bk_pop" href="#ndi.REF.takahashi.2012.2099">Takahashi et al 2012</a>].</p></div><div id="ndi.Nomenclature"><h3>Nomenclature</h3><p>The name "nephrogenic diabetes insipidus" was coined by Williams and Henry in 1947. In the literature it has been used synonymously with the terms "vasopressin- or ADH-resistant diabetes insipidus" or "diabetes insipidus renalis."</p></div><div id="ndi.Prevalence"><h3>Prevalence</h3><p>The exact prevalence of NDI is not known but it is assumed to be rare. The most recent estimate of the prevalence of NDI in Quebec, Canada is 8.8:1,000,000 males [<a class="bk_pop" href="#ndi.REF.arthus.2000.1044">Arthus et al 2000</a>]. In the Dutch population of approximately 16 million, 50 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families are known.</p></div></div><div id="ndi.Genetically_Related_Allelic_Disorder"><h2 id="_ndi_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b><i>AVPR2</i>.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <i>AVPR2</i> were reported to produce a very rare disorder called "nephrogenic syndrome of inappropriate antidiuresis" [<a class="bk_pop" href="#ndi.REF.feldman.2005.1884">Feldman et al 2005</a>, <a class="bk_pop" href="#ndi.REF.knoers.2005.1847">Knoers 2005</a>, <a class="bk_pop" href="#ndi.REF.levtchenko.2010.2839">Levtchenko &#x00026; Monnens 2010</a>].</p><p><b><i>AQP2</i>.</b> No other phenotypes are known to be associated with mutation of <i>AQP2</i>.</p></div><div id="ndi.Differential_Diagnosis"><h2 id="_ndi_Differential_Diagnosis_">Differential Diagnosis</h2><p>Diabetes insipidus is the excretion of abnormally large volumes (i.e., &#x0003e;50 mL/kg body weight in 24 hours) of dilute urine (i.e., specific gravity &#x0003c;1.010 or osmolality &#x0003c;300 mOsm/kg). In addition to inherited forms of nephrogenic diabetes insipidus (NDI), causes of diabetes insipidus include the following:</p><ul><li class="half_rhythm"><div><b>Deficiency in synthesis of the antidiuretic hormone</b> arginine vasopressin (AVP) in the supraoptic nuclei or secretion by the posterior pituitary (also called neurogenic, hypothalamic, cranial, central, or vasopressin-responsive diabetes insipidus).</div><ul><li class="half_rhythm"><div>Acquired causes include trauma, malignancy, granulomatous disease, infection, vascular disease, and autoimmune disease.</div></li><li class="half_rhythm"><div>Autosomal dominant neurogenic diabetes insipidus is caused by pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding prepro-arginine-vasopressin-neurophysin II (<i>prepro-AVP-NPII</i>).</div></li></ul></li><li class="half_rhythm"><div><b>Acquired nephrogenic diabetes insipidus</b> is much more common than the hereditary form of NDI, is usually less severe, and is associated with downregulation of <i>AQP2</i>. Known causes include prolonged lithium treatment; hypokalemia; hypercalcemia; vascular, granulomatous, and cystic kidney disease; infection; and urinary tract obstruction [<a class="bk_pop" href="#ndi.REF.khanna.2006.244">Khanna 2006</a>, <a class="bk_pop" href="#ndi.REF.wesche.2012.2183">Wesche et al 2012</a>]. Rarer reported causes include antibiotics and antifungal, antineoplastic, and antiviral agents [<a class="bk_pop" href="#ndi.REF.garofeanu.2005.626">Garofeanu et al 2005</a>].</div></li><li class="half_rhythm"><div><b>Primary polydipsia</b> may result from mental illness (called psychogenic polydipsia or compulsive water drinking) or disturbance of the thirst mechanism (called dipsogenic diabetes insipidus). The presence of plasma osmolarity greater than 295 mOsm/kg or serum sodium concentration greater than 143 mEq/L in the context of <i>ad libitum</i> fluid intake effectively excludes primary polydipsia.</div></li></ul><p><b>Diabetes mellitus.</b> Polyuria associated with diabetes mellitus is characterized by glucose in the urine and increased urine specific gravity.</p><p><b>Other.</b> Because of the nonspecific nature of the presenting signs of NDI, infants with NDI may go undiagnosed or be misdiagnosed while under care for failure to thrive, unexplained fever, urinary reflux, or other symptoms.</p></div><div id="ndi.Management"><h2 id="_ndi_Management_">Management</h2><div id="ndi.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with nephrogenic diabetes insipidus (NDI), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Renal ultrasound examination to evaluate for hydronephrosis, dilatation of the urinary tract, and megacystis</div></li><li class="half_rhythm"><div>Clinical genetics consultation</div></li></ul></div><div id="ndi.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management is usually best accomplished by a team consisting of a nutritionist, a pediatric (or adult) nephrologist or endocrinologist, and a clinical geneticist.</p><p><b>General management.</b> The essence of management is the provision of free access to drinking water and to toilet facilities. Infants, who are naturally unable to seek out water when thirsty, must be offered water between regular feedings. Children and adults who are heavy sleepers may need to be awakened at night by a family member or an alarm clock in order to drink water and to urinate. As long as an individual's thirst mechanism remains intact and the person is otherwise well, these measures prevent hypernatremic dehydration. Education of friends, teachers, caretakers, and neighbors and a willingness to find creative solutions are helpful.</p><p>Polyuria (and thus polydipsia) can be reduced by up to 50% without inducing hypernatremia by the use of one of the following drugs/combinations. Therapy is considered effective when urine output declines below a documented baseline in individuals with <i>ad libitum</i> water intake. Objective measurements of 24-hour urine volume are more valuable than subjective reports of the volume or frequency of voiding, although reduction in the latter provides a benefit to lifestyle.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Thiazide diuretics</b> (i.e., hydrochlorothiazide, chlorothiazide) in standard to high doses. Since these diuretics cause potassium wasting, serum potassium concentration should be monitored and supplemental potassium provided in the diet or pharmacologically as needed. Thiazides are often used in combination with either amiloride (a potassium-sparing diuretic) or indomethacin.</div><div class="half_rhythm">Note: When thiazide diuretic therapy is initiated, a transient increase in urine output may occur as a result of salt diuresis.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Dietary restriction of sodium</b> to 300 mg/day to maximize the effectiveness of thiazide diuretics in reducing urine output. Although previously a diet low in protein (2 g/kg/day) to reduce the renal osmolar load and obligatory water excretion was recommended, severe limitation of dietary protein may introduce nutritional deficiencies. Thus, it is preferable to prescribe dietary restriction of sodium only.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Nonsteroidal anti-inflammatory drugs (NSAIDs)</b>, such as indomethacin, to potentially improve urine concentrating ability and reduce urine output. NSAIDs have been used individually and in combination with thiazide diuretics (with or without amiloride). Because NSAIDs have undesirable effects, such as gastric and renal tubular damage, caution is warranted in the chronic use of NSAIDs for treatment of NDI.</div></li></ul><p><b>Emergency treatment for dehydration.</b> When individuals with NDI present with dehydration or shock, it is essential to establish whether the deficit is primarily in free water (through water deprivation or excessive urine, stool, or sweat) or in extracellular fluid (bleeding, fluid extravasation). The natural tendency of healthcare providers to treat dehydration with normal saline (0.9% NaCl) is dangerous in individuals with NDI if the deficit is primarily in free water.</p><ul><li class="half_rhythm"><div>Acute blood loss or shock may be treated with isotonic fluid until the blood pressure and heart rate are stabilized, after which 2.5% dextrose in water is the preferred solution.</div></li><li class="half_rhythm"><div>Dehydration associated with free water deficit is treated by gradually replacing the deficit water as well as ongoing urinary losses. Whenever possible, rehydration should occur with the oral intake of drinking water. If administration of IV fluids is required, 2.5% dextrose in water and/or quarter-normal saline should be used.</div></li></ul><p>If significant hypernatremia is present, serum sodium concentration should be monitored and the hydration solution modified to avoid reducing serum sodium concentration faster than 1 mEq/L per hour. Rapid increases or decreases in plasma osmolality can cause seizures, coma, brain damage, and death.</p><p><b>Special situations.</b> Individuals being prepared for surgery are often denied oral intake for many hours and are described as having "NPO" (nothing <i>per ora</i>) status. In individuals with NDI, an IV <b>must</b> be provided from the beginning of NPO status and the person's oral intake of water for that period, which is typically much larger than that of an individual who does not have NDI, should be given intravenously as 2.5% dextrose in water [<a class="bk_pop" href="#ndi.REF.moug.2005.89">Moug et al 2005</a>].</p><p><b>Hydronephrosis, hydroureter, and megacystis.</b> Treatment involves medical management to reduce urine output and continuous or intermittent bladder catheterization when significant post-void urinary bladder residuals are present.</p><p><b>Psychomotor development.</b> Children with a history of an episode of severe dehydration, delayed developmental milestones, or a delay in establishing the correct diagnosis and management warrant a formal developmental evaluation and intervention before school age.</p></div><div id="ndi.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Prevention of primary manifestations (see <a href="#ndi.Treatment_of_Manifestations">Treatment of Manifestations</a>) is possible when the diagnosis is made promptly after birth via <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. A genetic diagnosis may be performed after a few days; treatment and monitoring may then start immediately.</p></div><div id="ndi.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Prevention or reduction of serious renal, ureteral, or bladder dilatation may be achieved by reduction of urine production by drug therapy and voiding at two-hour intervals.</p></div><div id="ndi.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div class="half_rhythm">Monitoring of growth and development in infants and children</div></li><li class="half_rhythm"><div class="half_rhythm">Periodic measurement of serum sodium concentration to identify unrecognized hyperosmolality and early dehydration</div><div class="half_rhythm">Note: Urine output and urine specific gravity are useless as indicators of hydration status.</div></li><li class="half_rhythm"><div class="half_rhythm">Annual renal ultrasound evaluation to monitor for hydronephrosis and megacystis [<a class="bk_pop" href="#ndi.REF.shalev.2004.608">Shalev et al 2004</a>]</div></li></ul></div><div id="ndi.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Water intake must not be restricted.</p></div><div id="ndi.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to test at-risk infants for the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) as early as possible to allow for prompt diagnosis and treatment to reduce morbidity from hypernatremia, dehydration, and dilation of the urinary tract.</p><p>Since <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NDI is usually less severe than <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI, genetic testing of sibs of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children may be performed at a later stage.</p><p>Asymptomatic female family members of a male with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI who are at risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may undergo <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and genetic testing when they are of reproductive age.</p><p>See <a href="#ndi.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ndi.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Carriers of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> nephrogenic diabetes insipidus may experience a mild increase in urinary output and associated thirst during pregnancy.</p><p>No pregnancies in women with NDI resulting from two <i>AQP2</i> pathogenic variants have been reported to date.</p><p>Polyhydramnios is found in a minority of pregnancies in which the fetus is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by NDI. In cases of severe polyhydramnios and maternal discomfort, frequent amniotic fluid drainage may be necessary [<a class="bk_pop" href="#ndi.REF.kollamparambil.2011.653">Kollamparambil et al 2011</a>].</p></div><div id="ndi.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>In an individual with a milder <i>AVPR2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> resulting in a partial response to AVP and DDAVP<sup>&#x000ae;</sup>, high doses of DDAVP<sup>&#x000ae;</sup> in combination with a thiazide diuretic significantly decreased urinary volume [<a class="bk_pop" href="#ndi.REF.mizuno.2003.297">Mizuno et al 2003</a>]. Effectiveness and safety of this treatment in partial NDI needs to be explored further.</p><p>Because of the known gastrointestinal safety of selective cyclooxygenase (COX)-2 inhibitors compared to nonselective COX inhibitors (such as indomethacin), use of these drugs has been proposed for the treatment of NDI. The effectiveness of a specific COX-2 inhibitor in decreasing free water losses was demonstrated in male infants with NDI [<a class="bk_pop" href="#ndi.REF.pattaragarn.2003.1073">Pattaragarn &#x00026; Alon 2003</a>, <a class="bk_pop" href="#ndi.REF.soylu.2005.1814">Soylu et al 2005</a>]. However, in view of the recent discovery that prolonged use of this COX-2 inhibitor can cause severe cardiac side effects, it is not appropriate to use these inhibitors in the treatment of NDI until it has been determined which of the specific COX-2 inhibitors are completely safe.</p><p>Because in vitro expression studies reveal that the majority of <i>AVPR2</i> pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI and all <i>AQP2</i> pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI result in normal protein that is retained within the endoplasmic reticulum (ER), agents that restore plasma routing are under investigation as potential treatments. Promising agents for X-linked NDI are cell-permeable <i>AVPR2</i> antagonists or agonists that in vitro rescue the intracellular retention of several <i>AVPR2</i> mutants [<a class="bk_pop" href="#ndi.REF.morello.2000.887">Morello et al 2000</a>, <a class="bk_pop" href="#ndi.REF.tan.2003.35678">Tan et al 2003</a>, <a class="bk_pop" href="#ndi.REF.bernier.2004.2074">Bernier et al 2004</a>, <a class="bk_pop" href="#ndi.REF.robben.2006.379">Robben et al 2006</a>, <a class="bk_pop" href="#ndi.REF.robben.2007.f253">Robben et al 2007</a>, <a class="bk_pop" href="#ndi.REF.robben.2009.12195">Robben et al 2009</a>]. The feasibility of treatment with these so-called pharmacologic "chaperones" has recently been tested in vivo. In individuals with NDI who have <i>AVPR2</i> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, <a class="bk_pop" href="#ndi.REF.bernier.2006.232">Bernier et al [2006]</a> showed that treatment with a non-peptide V<sub>1a</sub> receptor antagonist had beneficial effects on urine volume and osmolality starting a few hours after administration. However, the long-term effect of this drug could not be tested because the clinical development of this V<sub>1a</sub> receptor antagonist was interrupted during the course of this study as a result of possible interference with the cytochrome P450 metabolic pathway. Confirmation of the putative beneficial effect of pharmacologic chaperones in NDI awaits further in vivo testing.</p><p>Aminoglycosides, such as gentamicin, allow read-through of stop codon variants in <i>AVPR2</i> in vitro, resulting in the production of full-length vasopressin V<sub>2</sub> receptor proteins [<a class="bk_pop" href="#ndi.REF.schulz.2002.5247">Schulz et al 2002</a>]. However, in view of the toxic effect of these antibiotics on the kidney, the application of such a therapy to NDI in the future is unlikely.</p><p>Another mechanism circumventing the vasopressin type-2 receptor has been tested in vitro. By stimulation of the E-prostanoid receptor EP4, NDI symptoms were greatly reduced in a conditional <i>AVPR2</i>-<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> mouse model [<a class="bk_pop" href="#ndi.REF.li.2009.3115">Li et al 2009</a>]. This was due to raised AQP2 levels, most probably as a consequence of cAMP production caused by EP4 stimulation. Recently, a similar effect was seen after stimulation of the EP2 receptor by the agonist butaprost [<a class="bk_pop" href="#ndi.REF.olesen.2011.12949">Olesen et al 2011</a>]. The EP2 receptor is a more interesting candidate for treatment of NDI than the EP4 receptor since EP2 agonists have already been tested in clinical studies for other diseases and have shown promising results concerning safety issues. However, clinical trials in NDI have not yet been performed and are necessary to evaluate the effects and safety of EP2 agonists for this disorder.</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="ndi.Genetic_Counseling"><h2 id="_ndi_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ndi.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Nephrogenic diabetes insipidus (NDI) may be transmitted in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked-recessive/">X-linked recessive</a> manner (90% of families), an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner (~9% of families), or an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner (~1% of families).</p></div><div id="ndi.Risk_to_Family_Members__XLinked_Inhe"><h3>Risk to Family Members &#x02013; X-Linked Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have NDI nor will he be a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Women who have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> son and another affected male relative are obligate heterozygotes.</div></li><li class="half_rhythm"><div>A positive family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance is observed in about half of X-linked cases [<a class="bk_pop" href="#ndi.REF.arthus.2000.1044">Arthus et al 2000</a>].</div></li><li class="half_rhythm"><div>Pedigree analysis reveals that in about half of families with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male, the affected male represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., an affected individual with no known family history of NDI); several possibilities regarding his mother's <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status need to be considered:</div><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AVPR2</i> and his mother is not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>;</div></li><li class="half_rhythm"><div>His mother has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AVPR2</i>, either (a) as a "<a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a>" (i.e., present at the time of her conception and therefore in every cell of her body) or (b) as "<a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>" (i.e., in some of her germ cells only);</div></li><li class="half_rhythm"><div>His maternal grandmother has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AVPR2</i>.</div></li></ul></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the proband's mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Male sibs who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; female sibs who inherit the pathogenic variant will be carriers and will usually not be affected.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the DNA of the mother of the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male in the family, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> All the daughters of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male are carriers; none of his sons will be affected.</p></div><div id="ndi.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Carrier testing by molecular analysis of at-risk female relatives is possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p></div><div id="ndi.Risk_to_Family_Members__Autosomal_Re"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents are obligate heterozygotes and therefore carry a single copy of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AQP2</i>.</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the chance of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>AQP2</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="ndi.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing by molecular analysis for at-risk family members is possible once the pathogenic variants have been identified in the family.</p></div><div id="ndi.Risk_to_Family_Members__Autosomal_Do"><h3>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The proportion of individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NDI who have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent is unknown because the number of reported cases is small.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NDI may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <i>de novo</i> pathogenic variants is unknown.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the proband's parent:</p><ul><li class="half_rhythm"><div>If a parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NDI is at a 50% risk of inheriting the <i>AQP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents. If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members are at risk.</p></div><div id="ndi.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ndi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ndi.Prenatal_Testing_and_Peimplantation"><h3>Prenatal Testing and Peimplantation Genetic Diagnosis</h3><p><b><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> NDI.</b> If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family, prenatal testing is possible for pregnancies at increased risk. The usual procedure is to determine fetal sex first. Noninvasive <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for fetal sex determination for women who are carriers of sex-linked conditions, such as NDI, is possible in some countries [<a class="bk_pop" href="#ndi.REF.devaney.2011.627">Devaney et al 2011</a>]. Fetal sex is determined on the presence/absence of Y <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> sequences in maternal blood. Fetal sex may also be determined by performing chromosome analysis on fetal cells obtained by chorionic villus sampling (usually performed at ~10-12 weeks' gestation) or by amniocentesis (usually performed at ~15-18 weeks' gestation). In case of a male fetus, fetal DNA can be analyzed for the known pathogenic variant.</p><p><b>Autosomal recessive NDI.</b> If the pathogenic variants have been identified in the family, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks' gestation) or chorionic villus sampling (usually performed at ~10-12 weeks' gestation).</p><p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p><p>Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p><p><b>Preimplantation genetic diagnosis (PGD)</b> may be an option for some families in which the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified.</p></div></div><div id="ndi.Resources"><h2 id="_ndi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</b></div><div><b>Phone:</b> 800-860-8747</div><div><b>Email:</b> healthinfo@niddk.nih.gov</div><div><a href="https://www.niddk.nih.gov/health-information/kidney-disease/diabetes-insipidus" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Diabetes Insipidus</a></div></li><li class="half_rhythm"><div><b>NDI Foundation</b></div><div>Main Street</div><div>P.O. Box 1390</div><div>Eastsound WA 98245</div><div><b>Phone:</b> 888-376-6343</div><div><b>Fax:</b> 888-376-6356</div><div><b>Email:</b> info@ndif.org</div><div><a href="https://ndif.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ndif.org</a></div></li><li class="half_rhythm"><div><b>European Rare Kidney Disease Reference Network (ERKNet)</b></div><div>Heidelberg </div><div>Germany</div><div><b>Phone:</b> 49-6221-56-2349</div><div><b>Fax:</b> 49-6221-56-5166</div><div><b>Email:</b> contact@erknet.org</div><div><a href="https://www.erknet.org/index.php?id=home" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.erknet.org</a></div></li></ul></div><div id="ndi.Molecular_Genetics"><h2 id="_ndi_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ndi.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Nephrogenic Diabetes Insipidus: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1177/table/ndi.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ndi.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ndi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ndi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ndi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ndi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ndi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ndi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ndi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/359" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>AQP2</i></a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=359" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12q13<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P41181" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Aquaporin-2</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/AQP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AQP2 database</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AQP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AQP2</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=AQP2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AQP2</a></td></tr><tr><td headers="hd_b_ndi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/554" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>AVPR2</i></a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=554" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq28</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P30518" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Vasopressin V2 receptor</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/AVPR2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AVPR2 @ LOVD</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=AVPR2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AVPR2</a></td><td headers="hd_b_ndi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=AVPR2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AVPR2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ndi.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ndi.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Nephrogenic Diabetes Insipidus (<a href="/omim/107777,125800,300538,304800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1177/table/ndi.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ndi.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/107777" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">107777</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AQUAPORIN 2; AQP2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/125800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">125800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIABETES INSIPIDUS, NEPHROGENIC, AUTOSOMAL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300538" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300538</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ARGININE VASOPRESSIN RECEPTOR 2; AVPR2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/304800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">304800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIABETES INSIPIDUS, NEPHROGENIC, X-LINKED</td></tr></tbody></table></div></div><div id="ndi.AVPR2"><h3><i>AVPR2</i></h3><p><b>Gene structure.</b>
<i>AVPR2</i> has three exons and two small introns. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1177/#ndi.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> More than 220 putative disease-causing variants have been identified [<a class="bk_pop" href="#ndi.REF.knoers.1999.344">Knoers &#x00026; Monnens 1999</a>, <a class="bk_pop" href="#ndi.REF.knoers.2001.1146">Knoers &#x00026; Deen 2001</a>, <a class="bk_pop" href="#ndi.REF.morello.2001.607">Morello &#x00026; Bichet 2001</a>, <a class="bk_pop" href="#ndi.REF.robben.2006.379">Robben et al 2006</a>] (update summarized in <a class="bk_pop" href="#ndi.REF.wesche.2012.2183">Wesche et al [2012]</a>). The variants are not clustered in one <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>AVPR2R</i> but are scattered throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. The pathogenic variants consist of single-nucleotide variants, small deletions and insertions, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, and large deletions of the 3' region [<a class="bk_pop" href="#ndi.REF.knoers.1999.344">Knoers &#x00026; Monnens 1999</a>, <a class="bk_pop" href="#ndi.REF.wesche.2012.2183">Wesche et al 2012</a>] or of the entire gene. For more information, see <a href="/books/NBK1177/#ndi.molgen.TA">Table A</a>.</p><div id="ndi.T.avpr2_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>AVPR2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1177/table/ndi.T.avpr2_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ndi.T.avpr2_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic alleles resulting in partial <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>&#x000a0;<sup>1</sup></td><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.253G&#x0003e;A</td><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp85Asn</td><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000054.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000054<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/4557345" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000045<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.602G&#x0003e;A</td><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly201Asp</td></tr><tr><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.964C&#x0003e;T</td><td headers="hd_h_ndi.T.avpr2_pathogenic_variants_discusse_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro322Ser</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature</p></div></dd><dt>1. </dt><dd><div id="ndi.TF.2.1"><p class="no_margin">See <a href="#ndi.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>AVPR2</i> encodes vasopressin V<sub>2</sub> receptor. The <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> predicts a polypeptide of 371 amino acids with seven transmembrane, four extracellular, and four cytoplasmic domains. The vasopressin V<sub>2</sub> receptor, a member of the G protein-coupled receptor superfamily, preferentially activates the G protein G<sub>s</sub> resulting in the activation of adenylyl cyclase. The first step in the antidiuretic action of AVP is binding the vasopressin V<sub>2</sub> receptor on the basolateral membrane of collecting duct cells. This step initiates a cascade of events &#x02013; receptor-linked activation of G protein (G<sub>s</sub>), activation of adenylyl cyclase, production of cyclic adenosine-monophosphate (cAMP), and stimulation of protein kinase A (PKA) &#x02013; that lead to the final step in the antidiuretic action of AVP, i.e., the exocytic <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of specific water channels AQP2, into the luminal membrane, thereby increasing the water permeability of that membrane.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most <i>AVPR2</i> pathogenic variants result in a receptor that is trapped intracellularly and unable to reach the plasma membrane [<a class="bk_pop" href="#ndi.REF.robben.2005.f265">Robben et al 2005</a>]. All <i>AVPR2</i> mutated alleles of individuals with classic NDI fail to signal with physiologic levels of AVP. A minority of mutated receptors reach the cell surface but are unable to bind to AVP or to trigger an intracellular cAMP signal [<a class="bk_pop" href="#ndi.REF.albertazzi.2000.1033">Albertazzi et al 2000</a>, <a class="bk_pop" href="#ndi.REF.pasel.2000.1703">Pasel et al 2000</a>, <a class="bk_pop" href="#ndi.REF.postina.2000.31">Postina et al 2000</a>, <a class="bk_pop" href="#ndi.REF.inaba.2001.381">Inaba et al 2001</a>].</p></div><div id="ndi.AQP2"><h3><i>AQP2</i></h3><p><b>Gene structure.</b>
<i>AQP2</i> has four exons (<a href="/nuccore/NM_000486.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000486.5</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1177/#ndi.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants</b></p><ul><li class="half_rhythm"><div><b>Autosomal recessive NDI.</b> More than 40 pathogenic variants that give rise to <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI have been detected in <i>AQP2</i>. These include 32 <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, two <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, two 1-bp deletions, one 2-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, and three <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants [<a class="bk_pop" href="#ndi.REF.knoers.1999.344">Knoers &#x00026; Monnens 1999</a>, <a class="bk_pop" href="#ndi.REF.knoers.2001.1146">Knoers &#x00026; Deen 2001</a>, <a class="bk_pop" href="#ndi.REF.morello.2001.607">Morello &#x00026; Bichet 2001</a>, <a class="bk_pop" href="#ndi.REF.lin.2002.2694">Lin et al 2002</a>, <a class="bk_pop" href="#ndi.REF.marr.2002a.2267">Marr et al 2002a</a>, <a class="bk_pop" href="#ndi.REF.tajima.2003.473">Tajima et al 2003</a>, <a class="bk_pop" href="#ndi.REF.iolascon.2007.33">Iolascon et al 2007</a>, <a class="bk_pop" href="#ndi.REF.sahakitrungruang.2008.210">Sahakitrungruang et al 2008</a>, <a class="bk_pop" href="#ndi.REF.moon.2009.905">Moon et al 2009</a>, <a class="bk_pop" href="#ndi.REF.wesche.2012.2183">Wesche et al 2012</a>].</div></li><li class="half_rhythm"><div><b>Autosomal dominant NDI.</b> Pathogenic variants (three <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, one 1-bp <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>, and four small deletions) identified in eight families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> NDI are located in the carboxy-terminal region of aquaporin-2, a region considered to be important for targeting of the protein [<a class="bk_pop" href="#ndi.REF.kamsteeg.1999.2394">Kamsteeg et al 1999</a>, <a class="bk_pop" href="#ndi.REF.kuwahara.2001.738">Kuwahara et al 2001</a>, <a class="bk_pop" href="#ndi.REF.marr.2002b.779">Marr et al 2002b</a>, <a class="bk_pop" href="#ndi.REF.sohara.2006.14217">Sohara et al 2006</a>, <a class="bk_pop" href="#ndi.REF.wesche.2012.2183">Wesche et al 2012</a>].</div></li></ul><p>For more information, see <a href="/books/NBK1177/#ndi.molgen.TA">Table A</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>AQP2</i> encodes aquaporin-2, the vasopressin-sensitive water channel of the renal collecting duct cells. Aquaporin-2 (AQP2) is one of a family of water-transporting proteins that facilitates osmotically driven water movement across plasma cell membranes. Vasopression, acting through cyclic AMP (cAMP) and protein kinase A (PKA) after binding to its V<sub>2</sub> receptor at the basolateral membrane of collecting duct cells, triggers the insertion of intracellular vesicles containing AQP2 proteins in the apical membrane, resulting in increased water permeability of this membrane. Phosphorylation of a PKA consensus site in AQP2 (serine at position 256 in the carboxy terminus) is essential for AQP2 delivery to the apical membrane [<a class="bk_pop" href="#ndi.REF.van_balkom.2002.41473">van Balkom et al 2002</a>]. Upon dissociation of AQP2 from its receptor, this process is rapidly reversed. This shuttling of AQP2 into and out of the apical membrane is responsible for the short-term regulation of collecting duct water permeability. Long-term regulation is a consequence of an increase in the expression level of AQP2 <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and protein.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b></p><ul><li class="half_rhythm"><div><b>Autosomal recessive NDI.</b> AQP2 mutated proteins show impaired transport from the endoplasmic reticulum to the plasma membrane, indicating that the major cause of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> NDI is misrouting of mutated AQP2 proteins.</div></li><li class="half_rhythm"><div><b>Autosomal dominant NDI.</b> Expression studies in <i>Xenopus</i> oocytes of the different AQP2 mutated proteins identified in individuals with the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of NDI showed that all these AQP2 mutated proteins are functional water channels, but on expression in polarized cells, it appeared that all mutants mistargeted to destinations in the cell other than the apical membrane destination of <a class="def" href="/books/n/gene/glossary/def-item/wild-type/">wild-type</a> AQP2. The AQP2 mutants form heterotetramers with the wild-type AQP2 and are inappropriately trafficked. Some heterotetramers were reported to traffick to the basolateral membrane, others to the Golgi complex, or to late endosomes/lysosomes. Formation of heterotetramers of mutated with wild-type AQP2 provides an explanation for the dominant behavior of these mutants. The fact that one sixteenth of all tetramers formed are wild type AQP2-only tetramers (which are normally trafficked to the apical membrane) explains the relatively milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in dominant NDI as compared to the recessive form [<a class="bk_pop" href="#ndi.REF.kamsteeg.1999.2394">Kamsteeg et al 1999</a>, <a class="bk_pop" href="#ndi.REF.marr.2002b.779">Marr et al 2002b</a>, <a class="bk_pop" href="#ndi.REF.asai.2003.2">Asai et al 2003</a>, <a class="bk_pop" href="#ndi.REF.kamsteeg.2003.1099">Kamsteeg et al 2003</a>, <a class="bk_pop" href="#ndi.REF.de_mattia.2005.2872">de Mattia et al 2005</a>].</div></li></ul></div></div><div id="ndi.References"><h2 id="_ndi_References_">References</h2><div id="ndi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.albertazzi.2000.1033">Albertazzi E, Zanchetta D, Barbier P, Faranda S, Frattini A, Vezzoni P, Procaccio M, Bettinelli A, Guzzi F, Parenti M, Chini B. Nephrogenic diabetes insipidus: functional analysis of new AVPR2 mutations identified in Italian families. <span><span class="ref-journal">J Am Soc Nephrol. </span>2000;<span class="ref-vol">11</span>:1033–43.</span> [<a href="/pubmed/10820167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10820167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.arthus.2000.1044">Arthus MF, Lonergan M, Crumley MJ, Naumova AK, Morin D, De Marco LA, Kaplan BS, Robertson GL, Sasaki S, Morgan K, Bichet DG, Fujiwara TM. Report of 33 novel AVPR2 mutations and analysis of 117 families with X- linked nephrogenic diabetes insipidus. <span><span class="ref-journal">J Am Soc Nephrol. </span>2000;<span class="ref-vol">11</span>:1044–54.</span> [<a href="/pubmed/10820168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10820168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.asai.2003.2">Asai T, Kuwahara M, Kurihara H, Sakai T, Terada Y, Marumo F, Sasaki S. Pathogenesis of nephrogenic diabetes insipidus by aquaporin-2 C-terminus mutations. <span><span class="ref-journal">Kidney Int. </span>2003;<span class="ref-vol">64</span>:2–10.</span> [<a href="/pubmed/12787389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12787389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.bernier.2004.2074">Bernier V, Lagace M, Lonergan M, Arthus MF, Bichet DG, Bouvier M. Functional rescue of the constitutively internalized V2 Vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. <span><span class="ref-journal">Mol Endocrinol. </span>2004;<span class="ref-vol">18</span>:2074–84.</span> [<a href="/pubmed/15166253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15166253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.bernier.2006.232">Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperriere A, Brouard R, Bouvier M, Bichet DG. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. <span><span class="ref-journal">J Am Soc Nephrol. </span>2006;<span class="ref-vol">17</span>:232–43.</span> [<a href="/pubmed/16319185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16319185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.de_mattia.2005.2872">de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, Oksche A, Deen PM. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. <span><span class="ref-journal">J Am Soc Nephrol. </span>2005;<span class="ref-vol">16</span>:2872–80.</span> [<a href="/pubmed/16120822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16120822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.devaney.2011.627">Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA. A systematic review and Meta-analysis. <span><span class="ref-journal">JAMA. </span>2011;<span class="ref-vol">306</span>:627–36.</span> [<a href="/pmc/articles/PMC4526182/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4526182</span></a>] [<a href="/pubmed/21828326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21828326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.faerch.2010.324">Faerch M, Corydon TJ, Rittig S, Christensen JH, Hertz JM, Jendle J. Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus. <span><span class="ref-journal">Scand J Urol Nephrol. </span>2010;<span class="ref-vol">44</span>:324–30.</span> [<a href="/pubmed/20459358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20459358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.feldman.2005.1884">Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. Nephrogenic syndrome of inappropriate antidiuresis. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:1884–90.</span> [<a href="/pmc/articles/PMC5340184/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5340184</span></a>] [<a href="/pubmed/15872203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15872203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.fenske.2011.1506">Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, Pfeiffer AF, Fassnacht M, St&#x000f6;rk S, Allolio B. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation tests. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:1506–15.</span> [<a href="/pubmed/21367924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21367924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.garofeanu.2005.626">Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF. Causes of reversible nephrogenic diabetes insipidus: a systematic review. <span><span class="ref-journal">Am J Kidney Dis. </span>2005;<span class="ref-vol">45</span>:626–37.</span> [<a href="/pubmed/15806465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15806465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.inaba.2001.381">Inaba S, Hatakeyama H, Taniguchi N, Miyamori I. The property of a novel v2 receptor mutant in a patient with nephrogenic diabetes insipidus. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2001;<span class="ref-vol">86</span>:381–5.</span> [<a href="/pubmed/11232028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11232028</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.iolascon.2007.33">Iolascon A, Aglio V, Tamma G, D'Apolito M, Addabbo F, Procino G, Simonetti MC, Montini G, Gesualdo L, Debler EW, Svelto M, Valenti G. Characterization of two novel missense mutations in the AQP2 gene causing nephrogenic diabetes insipidus. <span><span class="ref-journal">Nephron Physiol. </span>2007;<span class="ref-vol">105</span>:33–41.</span> [<a href="/pubmed/17192724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17192724</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.kamsteeg.2003.1099">Kamsteeg EJ, Bichet DG, Konings IB, Nivet H, Lonergan M, Arthus MF, van Os CH, Deen PM. Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. <span><span class="ref-journal">J Cell Biol. </span>2003;<span class="ref-vol">163</span>:1099–109.</span> [<a href="/pmc/articles/PMC2173618/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2173618</span></a>] [<a href="/pubmed/14662748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14662748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.kamsteeg.1999.2394">Kamsteeg EJ, Wormhoudt TA, Rijss JP, van Os CH, Deen PM. An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. <span><span class="ref-journal">EMBO J. </span>1999;<span class="ref-vol">18</span>:2394–400.</span> [<a href="/pmc/articles/PMC1171322/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1171322</span></a>] [<a href="/pubmed/10228154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10228154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.khanna.2006.244">Khanna A. Acquired nephrogenic diabetes insipidus. <span><span class="ref-journal">Semin Nephrol. </span>2006;<span class="ref-vol">26</span>:244–8.</span> [<a href="/pubmed/16713497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16713497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.kinoshita.2004.167">Kinoshita K, Miura Y, Nagasaki H, Murase T, Bando Y, Oiso Y. A novel deletion mutation in the arginine vasopressin receptor 2 gene and skewed X chromosome inactivation in a female patient with congenital nephrogenic diabetes insipidus. <span><span class="ref-journal">J Endocrinol Invest. </span>2004;<span class="ref-vol">27</span>:167–70.</span> [<a href="/pubmed/15129813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15129813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.knoers.2005.1847">Knoers NV. Hyperactive vasopressin receptors and disturbed water homeostasis. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:1847–50.</span> [<a href="/pubmed/15872199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15872199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.knoers.1999.344">Knoers NV, Monnens LL. Nephrogenic diabetes insipidus. <span><span class="ref-journal">Semin Nephrol. </span>1999;<span class="ref-vol">19</span>:344–52.</span> [<a href="/pubmed/10435672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10435672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.knoers.2001.1146">Knoers NV, Deen PM. Molecular and cellular defects in nephrogenic diabetes insipidus. <span><span class="ref-journal">Pediatr Nephrol. </span>2001;<span class="ref-vol">16</span>:1146–52.</span> [<a href="/pubmed/11793119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11793119</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.kollamparambil.2011.653">Kollamparambil TG, Mohan PV, Gunasuntharam K, Jani BR, Penman DG. Prenatal presentation of transient central diabetes insipidus. <span><span class="ref-journal">Eur J Pediatr. </span>2011;<span class="ref-vol">170</span>:653–6.</span> [<a href="/pubmed/21072537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21072537</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.kuwahara.2001.738">Kuwahara M, Iwai K, Ooeda T, Igarashi T, Ogawa E, Katsushima Y, Shinbo I, Uchida S, Terada Y, Arthus MF, Lonergan M, Fujiwara TM, Bichet DG, Marumo F, Sasaki S. Three families with autosomal dominant nephrogenic diabetes insipidus caused by aquaporin-2 mutations in the C-terminus. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:738–48.</span> [<a href="/pmc/articles/PMC1226060/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226060</span></a>] [<a href="/pubmed/11536078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11536078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.levtchenko.2010.2839">Levtchenko EN, Monnens LA. Nephrogenic syndrome of inappropriate antidiuresis. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2010;<span class="ref-vol">25</span>:2839–43.</span> [<a href="/pubmed/20543212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20543212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.li.2009.3115">Li JH, Chou CL, Li B, Gavrilova O, Eisner C, Schnermann J, Anderson SA, Deng CX, Knepper MA, Wess J. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:3115–26.</span> [<a href="/pmc/articles/PMC2752083/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2752083</span></a>] [<a href="/pubmed/19729836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19729836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.lin.2002.2694">Lin SH, Bichet DG, Sasaki S, Kuwahara M, Arthus MF, Lonergan M, Lin YF. Two novel aquaporin-2 mutations responsible for congenital nephrogenic diabetes insipidus in Chinese families. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2002;<span class="ref-vol">87</span>:2694–700.</span> [<a href="/pubmed/12050236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12050236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.marr.2002a.2267">Marr N, Bichet DG, Hoefs S, Savelkoul PJ, Konings IB, De Mattia F, Graat MP, Arthus MF, Lonergan M, Fujiwara TM, Knoers NV, Landau D, Balfe WJ, Oksche A, Rosenthal W, Muller D, Van Os CH, Deen PM. Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus. <span><span class="ref-journal">J Am Soc Nephrol. </span>2002a;<span class="ref-vol">13</span>:2267–77.</span> [<a href="/pubmed/12191971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12191971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.marr.2002b.779">Marr N, Bichet DG, Lonergan M, Arthus MF, Jeck N, Seyberth HW, Rosenthal W, van Os CH, Oksche A, Deen PM. Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin- 2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus. <span><span class="ref-journal">Hum Mol Genet. </span>2002b;<span class="ref-vol">11</span>:779–89.</span> [<a href="/pubmed/11929850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11929850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.mizuno.2003.297">Mizuno H, Fujimoto S, Sugiyama Y, Kobayashi M, Ohro Y, Uchida S, Sasaki S, Togari H. Successful treatment of partial nephrogenic diabetes insipidus with thiazide and desmopressin. <span><span class="ref-journal">Horm Res. </span>2003;<span class="ref-vol">59</span>:297–300.</span> [<a href="/pubmed/12784095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12784095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.moon.2009.905">Moon SS, Kim HJ, Choi YK, Seo HA, Jeon JH, Lee JE, Lee JY, Kwon TH, Kim JG, Kim BW, Lee IK. Novel mutation of aquaporin-2 gene in a patient with congenital nephrogenic diabetes insipidus. <span><span class="ref-journal">Endocr J. </span>2009;<span class="ref-vol">56</span>:905–10.</span> [<a href="/pubmed/19461158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19461158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.morello.2001.607">Morello JP, Bichet DG. Nephrogenic diabetes insipidus. <span><span class="ref-journal">Annu Rev Physiol. </span>2001;<span class="ref-vol">63</span>:607–30.</span> [<a href="/pubmed/11181969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11181969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.morello.2000.887">Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, Bouvier M. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. <span><span class="ref-journal">J Clin Invest. </span>2000;<span class="ref-vol">105</span>:887–95.</span> [<a href="/pmc/articles/PMC377482/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC377482</span></a>] [<a href="/pubmed/10749568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10749568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.olesen.2011.12949">Olesen ET, Rutzler MR, Moeller HB, Praetorius HA, Fenton RA. Vasopressin-independent targeting of aquaporin-2 E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2011;<span class="ref-vol">108</span>:12949–54.</span> [<a href="/pmc/articles/PMC3150913/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3150913</span></a>] [<a href="/pubmed/21768374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21768374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.moug.2005.89">Moug SJ, McKee RF, O'Reilly DS, Noble S, Boulton-Jones M. The perioperative challenge of nephrogenic diabetes insipidus: a multidisciplinary approach. <span><span class="ref-journal">Surgeon. </span>2005;<span class="ref-vol">3</span>:89–94.</span> [<a href="/pubmed/15861943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15861943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.pasel.2000.1703">Pasel K, Schulz A, Timmermann K, Linnemann K, Hoeltzenbein M, Jaaskelainen J, Gruters A, Filler G, Schoneberg T. Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2000;<span class="ref-vol">85</span>:1703–10.</span> [<a href="/pubmed/10770218" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10770218</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.pattaragarn.2003.1073">Pattaragarn A, Alon US. Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. <span><span class="ref-journal">Pediatr Nephrol. </span>2003;<span class="ref-vol">18</span>:1073–6.</span> [<a href="/pubmed/12883974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12883974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.postina.2000.31">Postina R, Ufer E, Pfeiffer R, Knoers NV, Fahrenholz F. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus. <span><span class="ref-journal">Mol Cell Endocrinol. </span>2000;<span class="ref-vol">164</span>:31–9.</span> [<a href="/pubmed/11026555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11026555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.robben.2005.f265">Robben JH, Knoers NV, Deen PM. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2005;<span class="ref-vol">289</span>:F265–72.</span> [<a href="/pubmed/16006591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16006591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.robben.2006.379">Robben JH, Sze M, Knoers NV, Deen PM. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. <span><span class="ref-journal">Mol Biol Cell. </span>2006;<span class="ref-vol">17</span>:379–86.</span> [<a href="/pmc/articles/PMC1345675/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1345675</span></a>] [<a href="/pubmed/16267275" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16267275</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.robben.2007.f253">Robben JH, Sze M, Knoers NV, Deen PM. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. <span><span class="ref-journal">Am J Physiol Renal Physiol. </span>2007;<span class="ref-vol">292</span>:F253–60.</span> [<a href="/pubmed/16926443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16926443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.robben.2009.12195">Robben JH, Kortenoeven ML, Sze M, Yae C, Milligan G, Oorschot VM, Klumperman J, Knoers NV, Deen PM. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2009;<span class="ref-vol">106</span>:12195–200.</span> [<a href="/pmc/articles/PMC2715499/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2715499</span></a>] [<a href="/pubmed/19587238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19587238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.schulz.2002.5247">Schulz A, Sangkuhl K, Lennert T, Wigger M, Price DA, Nuuja A, Gruters A, Schultz G, Schoneberg T. Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2002;<span class="ref-vol">87</span>:5247–57.</span> [<a href="/pubmed/12414899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12414899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.shalev.2004.608">Shalev H, Romanovsky I, Knoers NV, Lupa S, Landau D. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. <span><span class="ref-journal">Nephrol Dial Transplant. </span>2004;<span class="ref-vol">19</span>:608–13.</span> [<a href="/pubmed/14767016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14767016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.sahakitrungruang.2008.210">Sahakitrungruang T, Wacharasindhu S, Sinthuwiwat T, Supornsilchai V, Suphapeetiporn K, Shotelersuk V. Identification of two novel aquaporin-2 mutations in a Thai girl with congenital nephrogenic diabetes insipidus. <span><span class="ref-journal">Endocrine. </span>2008;<span class="ref-vol">33</span>:210–4.</span> [<a href="/pubmed/18473191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18473191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.sohara.2006.14217">Sohara E, Rai T, Yang SS, Uchida K, Nitta K, Horita S, Ohno M, Harada A, Sasaki S, Uchida S. Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2006;<span class="ref-vol">103</span>:14217–22.</span> [<a href="/pmc/articles/PMC1599937/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1599937</span></a>] [<a href="/pubmed/16968783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16968783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.soylu.2005.1814">Soylu A, Kasap B, Ogun N, Ozturk Y, Turkmen M, Hoefsloot L, Kavukcu S. Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus. <span><span class="ref-journal">Pediatr Nephrol. </span>2005;<span class="ref-vol">20</span>:1814–7.</span> [<a href="/pubmed/16240160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16240160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.tajima.2003.473">Tajima T, Okuhara K, Satoh K, Nakae J, Fujieda K. Two novel aquaporin-2 mutations in a sporadic Japanese patient with autosomal recessive nephrogenic diabetes insipidus. <span><span class="ref-journal">Endocr J. </span>2003;<span class="ref-vol">50</span>:473–6.</span> [<a href="/pubmed/14599123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14599123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.takahashi.2012.2099">Takahashi K, Makita N, Manaka K, Hisano M, Akioka Y, Miura K, Takubo N, Iida A, Ueda N, Hashimoto M, Fujita T, Igarashi T, Sekine T, Iiri T. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists. <span><span class="ref-journal">J Biol Chem. </span>2012;<span class="ref-vol">287</span>:2099–106.</span> [<a href="/pmc/articles/PMC3265889/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3265889</span></a>] [<a href="/pubmed/22144672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22144672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.tan.2003.35678">Tan CM, Nickols HH, Limbird LE. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:35678–86.</span> [<a href="/pubmed/12824183" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12824183</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.van_balkom.2002.41473">van Balkom BW, Savelkoul PJ, Markovich D, Hofman E, Nielsen S, van der Sluijs P, Deen PM. The role of putative phosphorylation sites in the targeting and shuttling of the aquaporin-2 water channel. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:41473–9.</span> [<a href="/pubmed/12194985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12194985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.van_lieburg.1999.1958">van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. <span><span class="ref-journal">J Am Soc Nephrol. </span>1999;<span class="ref-vol">10</span>:1958–64.</span> [<a href="/pubmed/10477148" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10477148</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.wesche.2012.2183">Wesche D, Deen PMT, Knoers NVAM. Congenital nephrogenic diabetes insipidus: the current state of affairs. <span><span class="ref-journal">Pediatr Nephrol. </span>2012;<span class="ref-vol">27</span>:2183–204.</span> [<a href="/pubmed/22427315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22427315</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ndi.REF.yoo.2006.126">Yoo TH, Ryu DR, Song YS, Lee SC, Kim HJ, Kim JS, Choi HY, Kang SW. Congenital nephrogenic diabetes insipidus presented with bilateral hydronephrosis: genetic analysis of V2R gene mutations. <span><span class="ref-journal">Yonsei Med J. </span>2006;<span class="ref-vol">47</span>:126–30.</span> [<a href="/pmc/articles/PMC2687569/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2687569</span></a>] [<a href="/pubmed/16502494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16502494</span></a>]</div></li></ul></div></div><div id="ndi.Chapter_Notes"><h2 id="_ndi_Chapter_Notes_">Chapter Notes</h2><div id="ndi.Author_History"><h3>Author History</h3><p>Nine Knoers, MD (2003-present) <br />Robert S Wildin, MD; Oregon Health and Science University (2000-2003)</p></div><div id="ndi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 June 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 March 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 June 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> no longer available on a clinical basis</div></li><li class="half_rhythm"><div>8 March 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 January 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 February 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 February 2000 (pb) Review posted live</div></li><li class="half_rhythm"><div>13 January 1999 (rw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1177</span><span class="label">PMID: <a href="/pubmed/20301356" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301356</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/nem/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/nephron-ov/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1177&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1177/?report=reader">PubReader</a></li><li><a href="/books/NBK1177/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1177" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1177" style="display:none" title="Cite this Page"><div class="bk_tt">Knoers N. Nephrogenic Diabetes Insipidus. 2000 Feb 12 [Updated 2012 Jun 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1177/pdf/Bookshelf_NBK1177.pdf">PDF version of this page</a> (468K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ndi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ndi.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ndi.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ndi.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ndi.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ndi.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ndi.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ndi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ndi.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ndi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ndi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=359[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AQP2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=554[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">AVPR2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1465484" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1465484" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1465484" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1465484" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27156763" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).</a><span class="source">[Best Pract Res Clin Endocrinol...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bichet DG, Bockenhauer D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Best Pract Res Clin Endocrinol Metab. 2016 Mar; 30(2):263-76. Epub 2016 Mar 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22503803" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Physiopathology and diagnosis of nephrogenic diabetes insipidus.</a><span class="source">[Ann Endocrinol (Paris). 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Physiopathology and diagnosis of nephrogenic diabetes insipidus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Devuyst O. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Endocrinol (Paris). 2012 Apr; 73(2):128-9. Epub 2012 Apr 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20374732" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> V2R mutations and nephrogenic diabetes insipidus.</a><span class="source">[Prog Mol Biol Transl Sci. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> V2R mutations and nephrogenic diabetes insipidus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bichet DG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Prog Mol Biol Transl Sci. 2009; 89:15-29. Epub 2009 Oct 7.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16580609" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nephrogenic diabetes insipidus.</a><span class="source">[Adv Chronic Kidney Dis. 2006]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nephrogenic diabetes insipidus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bichet DG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Chronic Kidney Dis. 2006 Apr; 13(2):96-104. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17081961" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Nephrogenic diabetes insipidus].</a><span class="source">[Nephrol Ther. 2006]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Nephrogenic diabetes insipidus].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bichet DG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nephrol Ther. 2006 Nov; 2(6):387-404. Epub 2006 Sep 25.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301356" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301356" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419f8dd21425a256290ca">Nephrogenic Diabetes Insipidus - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Nephrogenic Diabetes Insipidus - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:24:57-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8DA441E040621100000000088B02FA&amp;ncbi_session=CE8DA441E0419F81_2187SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1177%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1177&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1177/&amp;ncbi_pagename=Nephrogenic Diabetes Insipidus - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DA441E0419F81_2187SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>